Syncom Formulations (India) Limited

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication regarding Notice of 38th Annual General Meeting (AGM), Remote E-Voting, Book Closure and other details.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited reported strong Q1 FY 2026-27 results with 8% growth in consolidated income and 59% increase in profit before tax, driven by ethical prescription-led model and quality manufacturing.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has informed regarding the resignation of its Managing Director, Mr. Vijay Shankarlal Bankda, with effect from 11th August, 2026, due to leadership transition and effective succession planning.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has informed about the resignation of Mr. Kedarmal Shankarlal Bankda as Whole-Time Director, effective from 11th August, 2026, citing reasons of timely succession planning and health well-being.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has informed the Exchange about the submission of a copy of a newspaper publication related to the extract of un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The company has also announced the 42nd Annual General Meeting (AGM) of Vistar Amar Limited, a related party, which will be held on September 22, 2026.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has informed the Exchange about change in Management. The Board of Directors has approved the resignation of three key personnel: Shri Kedarmal Shankarlal Bankda, Shri Vijay Shankarlal Bankda, and Shri Rahul Vijay Bankda. Additionally, the Board has approved the appointment of Smt. Rinki Ankit Bankda as an Additional Director and further Designated as the Whole Time Director of the Company, and Shri Ankur Vijay Bankda as the Chief Financial Officer (CFO) under the category of Senior Management Personnel.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has informed the Exchange about General Updates regarding providing Remote E-Voting facilities for the 38th Annual General Meeting to be held on 30th September, 2026.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has informed the Exchange regarding Change in Auditors of the company. The Board of Directors has approved the appointment of M/s M. Goyal & Co. Cost Accountants as the Cost Auditor and M/s Bansal & Agrawal, Chartered Accountants as the Internal Auditor for the financial year 2026-27.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has submitted its un-audited standalone and consolidated financial results for the quarter ended 30th June, 2026, along with a limited review report. The results show a revenue from operations of Rs. 12465.95 lakhs and a total income of Rs. 13247.75 lakhs. The company has reported a profit before exceptional items and tax of Rs. 3190.88 lakhs and a net profit for the period from continuing operations of Rs. 2458.92 lakhs.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has announced a record date of 23-Sep-2026 for the purpose of dividend and meeting. The company will pay a 10% dividend, subject to approval by the members at their ensuing 38th Annual General Meeting.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has informed the Exchange that its Board of Directors has recommended a Final Dividend of Rs. 0.10 per equity share. The Record Date for determining the entitlement of members for payment of the dividend has been fixed as Wednesday, 23rd September, 2026. The 38th Annual General Meeting of the Company shall be held on Wednesday, 30th September, 2026.

Syncom Formulations (India) Limited

The Board of Directors of Syncom Formulations (India) Limited held a meeting on August 11, 2026, and approved various business items, including the unaudited financial results for the quarter ended June 30, 2026, and the appointment of new directors and officers. The meeting also noted the resignations of three directors and recommended a final dividend of 10% per equity share.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has announced the resignation of Mr. Vijay Shankarlal Bankda as Managing Director, effective August 11, 2026.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has announced the resignation of Mr. Rahul Vijay Bankda as Chief Financial Officer (CFO) with effect from August 11, 2026. The company has made the requisite disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has announced the resignation of Mr. Kedarmal Shankarlal Bankda as Whole-Time Director, effective August 11, 2026.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026, confirming the dematerialization of securities and listing on stock exchanges.

Syncom Formulations (India) Limited

Syncom Formulations (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.